JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

Key Points Despite their success, conventional and biologic disease-modifying antirheumatic drugs are not effective in all patients. First-generation Janus kinase (JAK) inhibitors, or jakinibs, are effective for rheumatoid arthritis and in a number of other autoimmune conditions. Next-generation sel...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Drug discovery 2017-12, Vol.16 (12), p.843-862
Hauptverfasser:	Schwartz, Daniella M., Kanno, Yuka, Villarino, Alejandro, Ward, Michael, Gadina, Massimo, O'Shea, John J.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/250/127 631/250/249/1313/498 631/250/249/2510 631/250/249/2510/257 631/250/249/2510/257/1402 631/92/613 692/308/153 Animals Biomedicine Biotechnology Cancer Research Care and treatment Cellular signal transduction Clinical trials Cytokines Cytokines - immunology Development and progression Drug Design Genetic aspects Health aspects Humans Immune System Diseases - drug therapy Immune System Diseases - physiopathology Immunologic diseases Inflammation - drug therapy Inflammation - physiopathology Inflammatory diseases Janus Kinase Inhibitors - adverse effects Janus Kinase Inhibitors - pharmacology Janus Kinase Inhibitors - therapeutic use Janus Kinases - drug effects Janus Kinases - metabolism Medicinal Chemistry Molecular Medicine Pharmacology/Toxicology Phosphotransferases review-article Signal Transduction - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!